Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Dooley

Showing results (181-190 of 263) with videos related to

Pageof 27
Sort By:
Clinical Pharmacology and Therapeutics|January 27, 2017
Defining the optimal dose of rifapentine for pulmonary tuberculosis: Exposure-response relations from two phase II clinical trialsR M Savic, M Weiner, W R MacKenzie, et al.
Frontiers in Pharmacology|July 16, 2021
The Population Pharmacokinetics of Meropenem in Adult Patients With Rifampicin-Sensitive Pulmonary TuberculosisAhmed A Abulfathi, Veronique de Jager, Elana van Brakel, et al.
Plos Medicine|January 4, 2017
Priority-Setting for Novel Drug Regimens to Treat Tuberculosis: An Epidemiologic ModelEmily A Kendall, Sourya Shrestha, Ted Cohen, et al.
Viruses|July 30, 2025
Evidence Generation for a Host-Response Biosignature of Respiratory DiseaseKelly E Dooley, Michael Morimoto, Piotr Kaszuba, et al.
Plos One|December 8, 2017
Isoniazid concentrations in hair and plasma area-under-the-curve exposure among children with tuberculosisVidya Mave, Aarti Kinikar, Anju Kagal, et al.
American Journal of Respiratory and Critical Care Medicine|January 17, 2020
Early Bactericidal Activity of Different Isoniazid Doses for Drug-Resistant Tuberculosis (INHindsight): A Randomized, Open-Label Clinical TrialKelly E Dooley, Sachiko Miyahara, Florian von Groote-Bidlingmaier, et al.
Antimicrobial Agents and Chemotherapy|April 1, 2015
Novel dosing strategies increase exposures of the potent antituberculosis drug rifapentine but are poorly tolerated in healthy volunteersKelly E Dooley, Radojka M Savic, Jeong-Gun Park, et al.
BMC Pediatrics|November 25, 2025
Longitudinal changes in screen time, sleep, and sports/exercise activity in early adolescenceJason M Nagata, Christiane K Helmer, Zain Memon, et al.
The Lancet. HIV|April 3, 2020
Once-weekly rifapentine and isoniazid for tuberculosis prevention in patients with HIV taking dolutegravir-based antiretroviral therapy: a phase 1/2 trialKelly E Dooley, Radojkam Savic, Akshay Gupte, et al.
Clinical Pharmacokinetics|March 6, 2021
Population Pharmacokinetics and Bayesian Dose Adjustment to Advance TDM of Anti-TB DrugsMarieke G G Sturkenboom, Anne-Grete Märtson, Elin M Svensson, et al.
Pageof 27

Showing results (181-190 of 263) with videos related to

Sort By:
Pageof 27
Clinical Pharmacology and Therapeutics|January 27, 2017
Defining the optimal dose of rifapentine for pulmonary tuberculosis: Exposure-response relations from two phase II clinical trialsR M Savic, M Weiner, W R MacKenzie, et al.
Frontiers in Pharmacology|July 16, 2021
The Population Pharmacokinetics of Meropenem in Adult Patients With Rifampicin-Sensitive Pulmonary TuberculosisAhmed A Abulfathi, Veronique de Jager, Elana van Brakel, et al.
Plos Medicine|January 4, 2017
Priority-Setting for Novel Drug Regimens to Treat Tuberculosis: An Epidemiologic ModelEmily A Kendall, Sourya Shrestha, Ted Cohen, et al.
Viruses|July 30, 2025
Evidence Generation for a Host-Response Biosignature of Respiratory DiseaseKelly E Dooley, Michael Morimoto, Piotr Kaszuba, et al.
Plos One|December 8, 2017
Isoniazid concentrations in hair and plasma area-under-the-curve exposure among children with tuberculosisVidya Mave, Aarti Kinikar, Anju Kagal, et al.
American Journal of Respiratory and Critical Care Medicine|January 17, 2020
Early Bactericidal Activity of Different Isoniazid Doses for Drug-Resistant Tuberculosis (INHindsight): A Randomized, Open-Label Clinical TrialKelly E Dooley, Sachiko Miyahara, Florian von Groote-Bidlingmaier, et al.
Antimicrobial Agents and Chemotherapy|April 1, 2015
Novel dosing strategies increase exposures of the potent antituberculosis drug rifapentine but are poorly tolerated in healthy volunteersKelly E Dooley, Radojka M Savic, Jeong-Gun Park, et al.
BMC Pediatrics|November 25, 2025
Longitudinal changes in screen time, sleep, and sports/exercise activity in early adolescenceJason M Nagata, Christiane K Helmer, Zain Memon, et al.
The Lancet. HIV|April 3, 2020
Once-weekly rifapentine and isoniazid for tuberculosis prevention in patients with HIV taking dolutegravir-based antiretroviral therapy: a phase 1/2 trialKelly E Dooley, Radojkam Savic, Akshay Gupte, et al.
Clinical Pharmacokinetics|March 6, 2021
Population Pharmacokinetics and Bayesian Dose Adjustment to Advance TDM of Anti-TB DrugsMarieke G G Sturkenboom, Anne-Grete Märtson, Elin M Svensson, et al.
Pageof 27